Treatment discontinuation and dosing information at 8-month follow-up
| Efficacy cohort . | MBC-CML . | LBC-CML . |
|---|---|---|
| No. patients | 74 | 42 |
| Still on treatment, no. (%) | 23 (31) | 5 (12) |
| Discontinued study therapy, no. (%) | 51 (69) | 37 (88) |
| Disease progression | 25 (34) | 22 (52) |
| Study drug toxicity | 8 (11) | 1 (2) |
| AE unrelated to study drug | 2 (3) | 0 (0) |
| Death | 7 (9) | 6 (14) |
| Noncompliance | 1 (1) | 0 (0) |
| Deterioration without progression | 2 (3) | 3 (7) |
| Other | 6 (8) | 5 (12) |
| Median duration of dasatinib therapy, mo (range) | ||
| Total treated population | 3.5 (0.03-12.0) | 2.8 (0.1-9.2) |
| Population still on study | 9.2 (7.8-12.0) | 8.3 (7.6-9.2) |
| Median of average daily dasatinib dose, mg/d | 137.0 | 140.0 |
| Efficacy cohort . | MBC-CML . | LBC-CML . |
|---|---|---|
| No. patients | 74 | 42 |
| Still on treatment, no. (%) | 23 (31) | 5 (12) |
| Discontinued study therapy, no. (%) | 51 (69) | 37 (88) |
| Disease progression | 25 (34) | 22 (52) |
| Study drug toxicity | 8 (11) | 1 (2) |
| AE unrelated to study drug | 2 (3) | 0 (0) |
| Death | 7 (9) | 6 (14) |
| Noncompliance | 1 (1) | 0 (0) |
| Deterioration without progression | 2 (3) | 3 (7) |
| Other | 6 (8) | 5 (12) |
| Median duration of dasatinib therapy, mo (range) | ||
| Total treated population | 3.5 (0.03-12.0) | 2.8 (0.1-9.2) |
| Population still on study | 9.2 (7.8-12.0) | 8.3 (7.6-9.2) |
| Median of average daily dasatinib dose, mg/d | 137.0 | 140.0 |